Search Within

Ross Levine

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Journal Article (202)
  2. Meeting Abstract (194)
  3. Editorial (11)
  4. Review (9)
  5. Research Letter (5)
  6. Book Section (2)
  7. Guidelines (2)
  8. Book Whole (1)
Groups
  1. Adult Leukemia (426)
  2. Center for Hematologic Malignancies (426)
  3. Center for Molecular Imaging and Biotechnology (426)
  4. Department of Medicine (426)
  5. Executive Committee, Center for Hematologic Malignancies (426)
  6. GSK Faculty (426)

More Groups

People
  1. Martin Tallman (50)
  2. Raajit Rampal (43)
  3. Eytan Stein (40)
  4. Franck Rapaport (28)
  5. Alan Shih (26)
  6. Maria Kleppe (26)

More People

Years
  1. 2024 (9)
  2. 2023 (26)
  3. 2022 (22)
  4. 2021 (25)
  5. 2020 (30)
  6. 2019 (29)

More Years

Publications
  1. Blood (159)
  2. Leukemia (16)
  3. Haematologica (14)
  4. Blood Advances (13)
  5. Cancer Research (12)
  6. Swiss Medical Weekly (11)

More Publications

Publishers
  1. American Society of Hematology (174)
  2. Nature Publishing Group (46)
  3. American Association for Cancer Research (36)
  4. Cell Press (25)
  5. Elsevier Inc. (15)
  6. Ferrata Storti Foundation (14)

More Publishers

Results (426)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The new science and concepts that underlie current and future treatments for myeloproliferative neoplasms
    Editorial

    Hoffman, R.; Levine, R.; Mascarenhas, J.; Rampal, R. K.
    Hematology/Oncology Clinics of North America (2021)

    Fulltext@MSK | Save
  • Epigenetic dysregulation of myeloproliferative neoplasms
    Review

    Dunbar, A.; Park, Y.; Levine, R.
    Hematology/Oncology Clinics of North America (2021)

    Fulltext@MSK | Save
  • Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the beat AML master trial
    Meeting Abstract

    Stein, E. M.; Huang, Y.; Borate, U.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Schiller, G. J.; Olin, R. L.; Foran, J. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Analysis of the global methylation profile of accelerated and blast phase myeloproliferative neoplasms and its association with response to decitabine-based therapy
    Meeting Abstract

    Rampal, R. K.; Yang, Q.; Koche, R. P.; McGovern, E.; Famulare, C.; Weinberg, R. S.; Mascarenhas, J.; Levine, R. L.; Hoffman, R.; Figueroa, M. E.
    Blood (2020)

    Fulltext@MSK | Save
  • Loss of LKB1/(STK11) facilitates leukemic progression of the myeloproliferative neoplasms
    Meeting Abstract

    Marinaccio, C.; Suraneni, P. K.; Celik, H.; Volk, A.; Wen, J. Q.; Ling, T.; Lasho, T.; Koche, R. P.; Famulare, C.; Stein, B. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Increased interleukin-8 (IL8)-CXCR2 signaling promotes progression of bone marrow fibrosis in myeloproliferative neoplasms
    Meeting Abstract

    Dunbar, A.; Lu, M.; Farina, M.; Park, Y.; Yang, J.; Kim, D.; Karzai, A.; Salama, M. E.; Snyder, J.; Krishnan, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Somatic mutations are shared between circulating endothelial cells (CEC) and CD34+ hematopoietic stem cells (HSC) in patients with primary myelofibrosis. Can PMF-initiating cells derive from a common HSC/EC precursor?
    Meeting Abstract

    Farina, M.; Bernardi, S.; Polverelli, N.; Zanaglio, C.; D'Adda, M.; Malagola, M.; Re, F.; Cattina, F.; Zollner, T.; Rossi, G.; more...
    Haematologica (2020)

    Fulltext@MSK | Save
  • A primary mouse model of AML as a new way to screen novel therapeutics and treatment combinations
    Meeting Abstract

    Johnson, M. L.; Elgamal, O. A.; Harrington, B.; Mustonen, A.; Lehman, A.; Bennett, C.; Dzwigalski, K. R.; Hill, K. L.; Phelps, M. A.; Truxall, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models
    Meeting Abstract

    Bhagwat, N.; Zhang, Y.; Lin, H.; Wang, M.; Rominger, D.; Emm, T.; Chugani-Mahtani, D.; Angelis, D.; Shetty, R.; Leal, R.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a potent therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save